{"prompt": "['Novartis', 'Confidential', 'Page 77', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', 'additional procedures for any purpose involving any investigational drugs under the protocol,', 'other than the purpose of the study. If despite this interdiction, data, information, observation', 'would be incidentally collected, the investigator shall immediately disclose it to Novartis and', 'not use it for any purpose other than the study, except for the appropriate monitoring on study', 'participants.', 'Investigators ascertain they will apply due diligence to avoid protocol deviations. If an', 'investigator feels a protocol deviation would improve the conduct of the study this must be', 'considered a protocol amendment, and unless such an amendment is agreed upon by Novartis', 'and approved by the IRB/IEC and health authorities, where required, it cannot be', 'implemented.', '11.1', 'Protocol amendments', 'Any change or addition to the protocol can only be made in a written protocol amendment that', 'must be approved by Novartis, health authorities where required, and the IRB/IEC prior to', 'implementation. Only amendments that are intended to eliminate an apparent immediate', 'hazard to patients may be implemented immediately provided the health authorities are', 'subsequently notified by protocol amendment and the reviewing IRB/IEC is notified.', 'Notwithstanding the need for approval of formal protocol amendments, the investigator is', 'expected to take any immediate action required for the safety of any patient included in this', 'study, even if this action represents a deviation from the protocol. In such cases, the reporting', 'requirements identified in Section 7 Safety Monitoring must be followed.', '12', 'References', 'References are available upon request.', 'ATS/ERS (2005) Recommendations for Standardized Procedures for Online and Offline', 'Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide. AJRCCM;', '171: 912-930.', 'Barnard J and Rubin DB (1999) Small-sample degrees of freedom with multiple imputation.', 'Biometrika; 86:948-955.', 'Bretz F, Maurer W, Brannath W et al. (2009) A graphical approach to sequentially rejective', 'multiple test procedures. Statistics in Medicine; 28(4): 586-604.', 'Carpenter JR, Roger JH, Kenward MG (2013) Analysis of Longitudinal Trials with Protocol', 'Deviation: A Framework for Relevant, Accessible Assumptions, and Inference via Multiple', 'Imputation. Journal of Biopharmaceutical Statistics, 23 (6), 1352-1371', 'Center for Disease Control and Prevention (Cdc.gov) (2000). Growth Charts - Homepage.', 'Available from: http://www.cdc.gov/growthcharts/', 'Chevalier E, Stock J, Fisher T et al. (2005) Cutting edge: chemoattractant receptor-', 'homologous molecule expressed on Th2 cells plays a restricting role on IL-5 production and', 'eosinophil recruitment. J Immunol; 175: 2056-2060.', 'Deng JW, Song IS, Shin HJ et al (2008) The effect of SLC01B1 * 15 in the disposition of', 'pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity', 'changes by SLC01B1*15. Pharmacogenetics and Genomics; 18(5): 424-433.']['Novartis', 'Confidential', 'Page 78', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', 'Elsby R, Hilgendorf C, and Fenner K (2012) Understanding the critical disposition pathways', \"of statins to assess drug-drug interaction risk during drug development: it's not just about\", 'OATP1B1. Clin Pharmacol and Ther; 92: 585-598.', 'Fuhlbrigge A, Reed ML, Stempel DA et al (2009) The status of asthma control in the U.S.', 'adult population. Allergy Asthma Proc 30: 529-533.', 'Global Initiative for Asthma (GINA) (2016). Global Strategy for Asthma Management and', 'Prevention. Available from http://www.ginasthma.org/', 'Global Initiative for Asthma (GINA) (2016). Pocket guide for asthma management and', 'prevention for adults and children older than 5 years. Available from', 'http://www.ginasthma.org/.', 'Jacobson TA (2008) Toward \"pain-free\" statin prescribing: clinical algorithm for diagnosis', 'and management of myalgia. Mayo Clin Proc; 83: 687-700.', \"Juniper EF, O'Byrne PM, Guyatt GH et al. (1999) Development and validation of a\", 'questionnaire to measure asthma control. Eur Resp J; 14: 902-907.', 'Juniper EF, Svensson K, Moerk AC, et al (2005) Modification of the Asthma Quality of Life', 'Questionnaire (standardised) for patients 12 years and older. Health and Quality of Life', 'Outcomes; 3: 58.', 'Juniper EF, Bousquet J, Abetz L et al., GOAL Committee (2006) Identifying \"well-controlled\\'', 'and \"not well-controlled\\' asthma using the Asthma Control Questionnaire. Respir Med; 100:', '616-621.', 'Juniper EF, Gruffydd-Jones K, Ward S, Svensson K (2010) Asthma Control Questionnaire in', 'children: Validation, measurement properties and interpretation of the Asthma Control', 'Questionnaire in children. Eur Respir J; 36: 1410-1416.', 'Kalliokoski A and Niemi M (2009) Impact of OATP transporters on pharmacokinetics. B J P;', '158: 693-705.', 'Malmstrom K, Rodriguez-Gomez G, Guerra J et al (1999) Oral montelukast, inhaled', 'beclomethasone, and placebo for chronic asthma. Ann Intern Med; 130: 487-495.', 'Masoli M, Fabian D, Holt S et al (2004) The global burden of asthma: executive summary of', 'the GINA Dissemination Committee Report. Allergy; 59: 469-478.', 'Noe J, Portmann R, Brun ME et al (2007) Substrate-dependent drug-drug interactions', 'between gemfibrozil, fluvastatin, and other organic anion-transporting peptide (OATP)', 'substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 35(8): 1308-1314.', 'Reddel HK, Taylor DR, Bateman ED et al. (2009) An official American Thoracic', 'Society/European Respiratory Society statement: asthma control and exacerbations:', 'standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care', 'Med; 180: 59-99.', 'Regan SL, Maggs JL, Hammond TG et al (2010) Acyl glucuronides: the good, the bad and the', 'ugly. Biopharm Drug Dispos; 31:367-395.']\n\n###\n\n", "completion": "END"}